The acquired resistance to the combination of the anti-EGFR cetuximab and the MEK-inhibitor refametinib in KRAS mutated colorectal cancer cell lines depends on PI3K-signalling

Authors :: N. Zanaletti
P. Vitale
Claudia Cardone
M. R. Diadema
Gianpaolo Papaccio
Floriana Morgillo
Teresa Troiani
Stefania Napolitano
Giulia Martini
Vincenzo Sforza
Fortunato Ciardiello
Emilio Francesco Giunta
Valentina Belli
V. De Falco
Nunzia Matrone
Davide Ciardiello
Erika Martinelli
Vincenzo Desiderio
Paola Vitiello
Source :: Annals of Oncology. 28:v2
Publication Year :: 2017
Publisher :: Elsevier BV, 2017.

Subjects :: Oncology
medicine.medical_specialty
Cetuximab
Colorectal cancer
business.industry
MEK inhibitor
Hematology
medicine.disease
medicine.disease_cause
Signalling
Cell culture
Internal medicine
medicine
KRAS
Refametinib
business
PI3K/AKT/mTOR pathway
medicine.drug

Tools